Novo Nordisk makes headway in bid to rule obesity market with stunning phase 3 semaglutide data


Life Science Washington member Novo Nordisk has taken one step forward in its ambition to move its Type 2 diabetes drug semaglutide into the obesity market. Data from a newly-released phase 3 trial showed that one-third of patients taking semaglutide lost more than 20% of their body weight during the 68-week trial. The average participant lost more than 33 pounds, and many saw improvements in risk factors for diabetes and heart disease, according to University College London, one of the principle trial sites.